Hill-Rom Holdings, Inc. (HRC) Holdings Increased by Piedmont Investment Advisors Inc.

Piedmont Investment Advisors Inc. raised its holdings in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 34,511.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 3,115 shares of the medical technology company’s stock after purchasing an additional 3,106 shares during the period. Piedmont Investment Advisors Inc.’s holdings in Hill-Rom were worth $294,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Xact Kapitalforvaltning AB increased its position in shares of Hill-Rom by 8.6% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 8,802 shares of the medical technology company’s stock valued at $769,000 after purchasing an additional 700 shares during the period. Legal & General Group Plc increased its position in shares of Hill-Rom by 0.9% during the 2nd quarter. Legal & General Group Plc now owns 86,984 shares of the medical technology company’s stock valued at $7,597,000 after purchasing an additional 767 shares during the period. Creative Planning increased its position in shares of Hill-Rom by 4.0% during the 3rd quarter. Creative Planning now owns 20,694 shares of the medical technology company’s stock valued at $1,954,000 after purchasing an additional 794 shares during the period. Yorktown Management & Research Co Inc increased its position in shares of Hill-Rom by 34.8% during the 3rd quarter. Yorktown Management & Research Co Inc now owns 3,100 shares of the medical technology company’s stock valued at $293,000 after purchasing an additional 800 shares during the period. Finally, Swiss National Bank increased its position in shares of Hill-Rom by 0.8% during the 3rd quarter. Swiss National Bank now owns 115,600 shares of the medical technology company’s stock valued at $10,913,000 after purchasing an additional 900 shares during the period. 79.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of HRC stock opened at $93.45 on Monday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.30 and a current ratio of 1.74. The firm has a market cap of $6.29 billion, a PE ratio of 19.67, a PEG ratio of 1.30 and a beta of 0.90. Hill-Rom Holdings, Inc. has a 1 year low of $78.16 and a 1 year high of $98.96.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.12. The business had revenue of $759.20 million for the quarter, compared to analysts’ expectations of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. The company’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.32 EPS. As a group, research analysts expect that Hill-Rom Holdings, Inc. will post 5.13 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Friday, December 14th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Thursday, December 13th. Hill-Rom’s payout ratio is 16.84%.

HRC has been the topic of several research analyst reports. Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Barclays initiated coverage on Hill-Rom in a research report on Monday, October 15th. They set an “equal weight” rating and a $95.00 price target on the stock. Raymond James lifted their price target on Hill-Rom from $97.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, July 30th. Finally, Morgan Stanley lifted their price target on Hill-Rom from $95.00 to $100.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $100.33.

WARNING: This piece was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.wkrb13.com/2018/11/26/hill-rom-holdings-inc-hrc-holdings-increased-by-piedmont-investment-advisors-inc.html.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Further Reading: Investing in Dividend Stocks

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply